Xu ZY - Search Results

1

Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis.

Hu H, Xu ZY, Zhu Q, Liu X, Jiang SC, Zheng JH. Hu H, et al. Among authors: xu zy. Front Immunol. 2021 Jul 14;12:669398. doi: 10.3389/fimmu.2021.669398. eCollection 2021. Front Immunol. 2021. PMID: 34335570 Free PMC article.

2

[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].

Zhou J, Zhang WM, Chen H, Xie B, Zheng JH, Xu ZY, Lin JR. Zhou J, et al. Among authors: xu zy. Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):867-72. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 20137355 Chinese.

3

[The retrospective analysis of different therapies on 150 elderly patients with advanced non-small cell lung cancer.].

Zheng J, Zhang W, Chen H, Xu Z, Zhou J, Xie B, Li L, Lin J. Zheng J, et al. Zhongguo Fei Ai Za Zhi. 2009 Feb 20;12(2):122-6. doi: 10.3779/j.issn.1009-3419.2009.02.05. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20716404 Free article. Chinese.

4

Estrogen decreases anoikis of ovarian cancer cell line Caov-3 through reducing release of Bit1.

Zheng J, Zhou J, Xie X, Xie B, Lin J, Xu Z, Zhang W. Zheng J, et al. DNA Cell Biol. 2014 Dec;33(12):847-53. doi: 10.1089/dna.2014.2453. DNA Cell Biol. 2014. PMID: 25211327

5

Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.

Zhou J, Hu Q, Zhang X, Zheng J, Xie B, Xu Z, Zhang W. Zhou J, et al. Oncol Rep. 2018 Apr;39(4):1783-1792. doi: 10.3892/or.2018.6242. Epub 2018 Feb 1. Oncol Rep. 2018. PMID: 29393480

6

Association of menopausal status with COVID-19 outcomes: a propensity score matching analysis.

Wang XW, Hu H, Xu ZY, Zhang GK, Yu QH, Yang HL, Zheng JH. Wang XW, et al. Among authors: xu zy. Biol Sex Differ. 2021 Jan 29;12(1):16. doi: 10.1186/s13293-021-00363-6. Biol Sex Differ. 2021. PMID: 33514386 Free PMC article.

7

The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients with lung cancer.

Hu H, Zhu Q, Tang H, Zhang SC, Huang YZ, Wang YF, Xu ZY, Yang XW, Zheng JH, Guo CY. Hu H, et al. Among authors: xu zy. Int J Cancer. 2025 Feb 1;156(3):608-622. doi: 10.1002/ijc.35195. Epub 2024 Sep 25. Int J Cancer. 2025. PMID: 39319530

8

Venous thromboembolism in patients with severe lung cancer: a narrative review.

Zheng LX, Li L, Huang JH, Mai YM, Chen C, Dong JH, Xu ZY, Li WF, Chen XR. Zheng LX, et al. Among authors: xu zy. Ann Palliat Med. 2021 Jun;10(6):6957-6967. doi: 10.21037/apm-21-1281. Epub 2021 Jun 7. Ann Palliat Med. 2021. PMID: 34118860 Free article. Review.

9

MARCH1 as a novel immune-related prognostic biomarker that shapes an inflamed tumor microenvironment in lung adenocarcinoma.

Xu Z, Liu J, Liu Z, Zhang H. Xu Z, et al. Front Oncol. 2022 Oct 13;12:1008753. doi: 10.3389/fonc.2022.1008753. eCollection 2022. Front Oncol. 2022. PMID: 36313698 Free PMC article.

10

Long noncoding RNA CASC9.5 promotes the proliferation and metastasis of lung adenocarcinoma.

Zhou J, Xiao H, Yang X, Tian H, Xu Z, Zhong Y, Ma L, Zhang W, Qiao G, Liang J. Zhou J, et al. Sci Rep. 2018 Jan 8;8(1):37. doi: 10.1038/s41598-017-18280-3. Sci Rep. 2018. PMID: 29311567 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

954 results

Search Page

Filters